JAK-mutant myeloproliferative neoplasms.

Area of Science:

• Oncology
• Molecular Biology
• Signal Transduction

Background:

• The Janus kinase (JAK) family, including JAK1, JAK2, JAK3, and TYK2, plays a crucial role in cellular signaling.
• Recent discoveries highlight the significance of JAK activation in human malignancies, particularly BCR-ABL-negative myeloproliferative neoplasms (MPN).

Purpose of the Study:

• To review genetic alterations activating JAK signaling in various cancers.
• To discuss the development of small-molecule JAK inhibitors for cancer therapy.

Main Methods:

• Literature review of studies identifying genetic alterations in JAK signaling pathways.
• Analysis of research on small-molecule inhibitors targeting JAK kinase activity.

Main Results:

• A recurrent JAK2V617F mutation is found in most patients with MPN, polycythemia vera, essential thrombocytosis, and primary myelofibrosis.
• Other JAK-STAT pathway-activating mutations identified in MPN and leukemia subsets.
• Dysregulated JAK-STAT signaling implicated in epithelial neoplasms.

Conclusions:

• Genetic alterations activating JAK signaling are implicated in diverse malignancies.
• Small-molecule JAK inhibitors represent a promising therapeutic strategy for MPNs and other cancers.